Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Staar Surgical Earnings Call: Key Takeaways

STAAR Surgical delivered record nine-month revenue driven by a structural shift from lasers to lenses, though supply constraints in China and temporary margin pressures from ERP implementation impacted the quarter.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthChina 31% (adj), Americas 14%, EMEA 31%, APAC ex-China 4%.
Mgmt ConfidenceConfident in long-term laser-to-lens shift; cautious on near-term macro/geopolitical outlook.
Demand VisibilityChina in-market unit shipments grew 12.4%; supply unable to meet demand.
Order BookDistributor inventory below six-month target; working through US MTO backlog.
Margin TrendsQ3 gross margin 70.9% vs 75.5% (adj); temporary ERP/tariff pressures.
Op. LeverageYield improvements of 1% generate $750k-$1M in annual incremental profit.
Pricing PowerHigher ASPs driven by mix shift to EVO Plus and Toric.
Vol vs PriceChina net sales growth entirely price/mix-led due to supply constraints.
Segment GrowthEVO Plus and Toric lenses driving premium mix and ASP growth.
New ClientsHundreds of mid-tier Chinese hospitals closing gap with established centers.
Capex & DebtDebt-free; $206.4M cash; $50M share repurchase program authorized.
RegulatoryAwaiting regulatory authorizations for first-in-human Presbyopia trials; US label expanded.
CommentaryStrategic focus on 'Innovation Acceleration' across product, commercial, and operational areas.
New LaunchesEVO Plus launched in China; two Presbyopia products entering human trials.

Growth

Excluding China deferred sales, Q3 net sales grew 21%; China grew 31% and Americas 14%.

Outlook

Expects 2027 gross margin improvement; authorized $50 million share repurchase; Presbyopia trials starting in months.

Risks

Management used vague language regarding Q4 guidance and 2027 outlook, citing macro and geopolitical unknowns.

Source

The company's earnings call, NASDAQ: STAA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Staar Surgical Co: key numbers

Share price
$26.01Close, Nov 16
Market cap
$1.31B
Shares outstanding
50.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Ophthalmic GoodsSIC 3851

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Staar Surgical Co

All →
4:09 PM ET 10-Q
Financial Results ▶ Call

Staar Surgical Q3 2026 Results: Net Income $5.58M, Down 37.2% YoY

STAAR Surgical reported net income of $18.8 million for the first nine months of 2026, a significant recovery from a net loss of $62.1 million in the prior year period. Net sales grew to $270.5 million from $181.6 million year-over-year, driven by improved operating income and reduced restructuring and impairment charges.

Key figure
Net income $5.58M · -37.2% YoY
4:03 PM ET 8-K
Financial Results

Staar Surgical Financial Results

STAAR Surgical reported third quarter 2026 net sales of $83.4 million and net income of $5.6 million. The company achieved record year-to-date revenue of $270.5 million and authorized a new $50 million share repurchase program during the period.

Term
Q3 2026
12:26 PM ET 8-K/A
Executive Compensation

Staar Surgical Executive Compensation

STAAR Surgical Company appointed former CEO David Bailey as Chief Commercial Officer, effective September 8, 2026. His compensation package includes an annual base salary of approximately $575,000, a target cash bonus of 60% of base salary, and initial equity grants totaling $2.25 million in value (comprised of an $850,000 sign-on grant and a $1.4 million annual long-term incentive award).

Counterparty
David Bailey

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.